Patents Examined by Changhwa J. Cheu
  • Patent number: 10114027
    Abstract: This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to ?-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-?-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-?-glucan antibody.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: October 30, 2018
    Assignee: Biothera, Inc.
    Inventors: Nandita Bose, Mary A. Antonysamy, Keith B. Gorden, Richard Walsh, Michael E. Danielson, Peter Maimonis
  • Patent number: 10106575
    Abstract: The invention provides binding agents and assays tor insulin signal peptide. The agents and assays are useful in methods tor predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: October 23, 2018
    Assignee: Upstream Medical Technologies Limited
    Inventors: Christopher Joseph Pemberton, Arthur Mark Richards, Michael Gary Nicholls, Timothy Grant Yandle
  • Patent number: 10107802
    Abstract: The present invention provides a technique that suppresses a background value of a detection signal to construct an immunoassay system that detects a modified nucleobase. Specifically, the present invention provides a method for measuring a modified nucleobase including incubating a nucleic acid sample, a capture probe, and a solid phase probe in a solution and measuring a modified nucleobase using an antibody against the modified nucleobase in the obtained solution. The present invention also provides a kit for measuring a modified nucleobase including a capture probe, a solid phase probe, and an antibody against a modified nucleobase.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: October 23, 2018
    Assignee: FUJIREBIO INC.
    Inventors: Tatsuki Matsuno, Mariko Horiike
  • Patent number: 10088489
    Abstract: The present disclosure relates to assays and methods for the detection of renal inflammation by measuring the level of P2Y14 and/or UDP-glucose in a sample from a subject, such as a urine sample. The present disclosure also relates to methods for the treatment of renal inflammation by administering a P2Y14 inhibitor.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: October 2, 2018
    Assignee: The General Hospital Corporation
    Inventors: Sylvie Breton, Dennis Brown, Anie Azroyan, Virna F. Cortez-Retamozo, Mikael Pittet
  • Patent number: 10088479
    Abstract: The invention relates to a method of determining the inflammatory disorder status of a subject comprising detecting the presence or absence, or the level, of (i) citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C; and/or (ii) autoantibodies with specificity for citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C, in a sample from said subject.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: October 2, 2018
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Kim Suzanne Midwood, Patrick John Venables
  • Patent number: 10077285
    Abstract: Compositions, methods, articles of manufacture, and kits are provided for storage and delivery of proteins.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: September 18, 2018
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Clayton T. McKee, William Strong
  • Patent number: 10078092
    Abstract: Aspects of the invention relate to methods for measuring the binding constant of a lipophilic or amphiphilic molecule acceptor for a lipophilic or amphiphilic molecule. Methods involve rapid, cell-free competition assays including a labeled lipophilic or amphiphilic molecule and nanoparticle.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 18, 2018
    Assignee: Northwestern University
    Inventors: Raja Kannan Mutharasan, C. Shad Thaxton
  • Patent number: 10073109
    Abstract: Disclosed are genetically-modified phages, comprising a first nucleic acid sequence encoding at least a first peptide able to bind to a magnetic nanoparticle, and a second nucleic acid sequence encoding at least a second peptide able to bind with high specificity to a predetermined biomarker, and a method for using the genetically-modified phage displaying the first peptide and second peptide in a method for analyzing a fluid sample for the predetermined biomarker.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: September 11, 2018
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Chuanbin Mao, Binrui Cao
  • Patent number: 10073090
    Abstract: Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: September 11, 2018
    Assignee: ABBOTT LABORATORIES
    Inventors: Barry L. Dowell, Susan Gayda, Qiaoqiao Ruan, Joseph P. Skinner, Sergey Y. Tetin
  • Patent number: 10067146
    Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: September 4, 2018
    Assignee: Critical Care Diagnostics, Inc.
    Inventors: James V. Snider, Sven Jacobson
  • Patent number: 10060911
    Abstract: The present invention relates to a novel method for diagnosing high-affinity binders, in particular antibodies or autoantibodies, and the identification, characterization and selection of marker sequences and diagnostic use thereof, in particular in the form of a panel. The invention also relates to a singleplex assay in which the discovered selection of marker sequences is used in the form of a panel and high-affinity binders are detected using a single signal.
    Type: Grant
    Filed: August 18, 2012
    Date of Patent: August 28, 2018
    Assignee: Protagen Aktiengesellschaft
    Inventors: Stefan Müllner, Peter Schulz-Knappe, Angelika Lueking, Heike Göhler, Jessica Schwermann
  • Patent number: 10060925
    Abstract: The invention relates to compositions and methods for detecting renal injury in a subject, such as proximal tubular injury associated with acute kidney injury.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 28, 2018
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Joseph P. Gaut, Jack Ladenson, Dan Crimmins, Vijay Modur
  • Patent number: 10060912
    Abstract: Methods for proteomic screening on random protein-bead arrays by mass spec is described. Photocleavable mass tags are utilized to code a protein library (bait molecules) displayed on beads randomly arrayed in an array substrate. A library of probes (prey) can be mixed with the protein-bead array to query the array. Because mass spec can detect multiple mass tags, it is possible to rapidly identify all of the interactions resulting from this mixing.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: August 28, 2018
    Assignee: AmberGen, Inc.
    Inventors: Mark J Lim, Vladislav B Bergo, Kenneth J Rothschild
  • Patent number: 10048266
    Abstract: We identified >40 proteins that elicited at least a 2-fold increase in antibody response post-pancreatic-cancer vaccination, from each of three patients' sera. The antibody responses detected against these proteins in patients with >3 years disease-free survival indicates the anti-tumor potential of targeting these proteins. We found that tissue expression of proteins PSMC5, TFRC and PPP1R12A increases during tumor development from normal to pre-malignant to pancreatic tumor. In addition, these proteins were shown to be pancreatic cancer-associated antigens that are recognized by post-vaccination antibodies in the sera of patients that received the vaccine and have demonstrated a favorable disease free survival.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: August 14, 2018
    Assignee: The Johns Hopkins University
    Inventors: Elizabeth A. Jaffee, Darshil T. Jhaveri, Robert Anders
  • Patent number: 10041961
    Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Insulin Receptor protein (IR), and its isoforms IR-A and IR-B, that are particularly advantageous for quantifying the IR protein, IR-A isoform and/or IR-B isoform, directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: August 7, 2018
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
  • Patent number: 10036759
    Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: July 31, 2018
    Assignee: Nestec S.A.
    Inventors: Stefan Westin, Fabiyola Selvaraj, Fred Princen, Sharat Singh
  • Patent number: 10006906
    Abstract: This disclosure describes assay methods and kits for detecting a target. The methods and kits can be used to detect a target that is present in a sample at low concentration because the methods and kits amplify the signal indicating the presence of target in the sample. Generally, the methods and kits involve nanoparticle aggregation as a detectable signal that is enhanced by a trigger released from a vesicular compartment when the target is bound to a capture agent.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: June 26, 2018
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventor: Abdennour Abbas
  • Patent number: 10001490
    Abstract: Provided is a method of bioassay for the quantification of peptide fragments elevated in lung diseases such as COPD, SCC, or IPF. The peptide fragments comprise a neo-epitope formed at a cleavage site by cleavage in vivo of elastin by a proteinase. In the method a sample is contacted with an antibody having specific binding affinity for the neo-epitope amino acid sequence and determining the level of binding is determined where the antibody binds one of the following terminal sequences: . . . FGPGVV, . . . VPGLGV or IKAPKL . . . . Also provided are antibodies and immunoassay kits for use in such methods.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: June 19, 2018
    Assignee: Nordic Bioscience A/S
    Inventors: Jacob Hull Kristensen, Diana Julie Oersnes-Leeming, Morten Karsdal
  • Patent number: 9983214
    Abstract: The invention provides a method for determining the efficacy of compositions used to treat articular joint conditions in mammals. The method includes measuring the change in levels of one or more cartilage degradation biomarkers in a mammal from before exercise and after exercise, then administering a composition used to treat articular joint conditions to the mammal, and measuring the change in levels of one or more cartilage degradation biomarkers in the mammal from before exercise and after exercise.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 29, 2018
    Assignee: ESM Technologies, LLC
    Inventor: Kevin J. Ruff
  • Patent number: 9983215
    Abstract: Methods and compositions are provided for diagnosing ectopic pregnancy in a mammalian subject by detecting changes in expression of the selected genes, gene fragments or transcripts or expression products, or changes in the expression levels of one or more of proteins or peptide fragments, identified in Table 2 and FIGS. 8 and 9 herein. A selected gene, gene transcript or protein/peptide expression product, or profiles or signatures formed by combinations of same, detected in a biological fluid, preferably sera, of a subject, enables comparison of the corresponding genes, proteins or profiles from that of a reference or control having a normal intrauterine pregnancy. Detection of characteristic changes in the gene profile or protein expression signature of the subject is correlated with a diagnosis of ectopic pregnancy.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 29, 2018
    Assignees: The Wistar Institute of Anatomy and Biology, The Trustees of the University of Pennsylvania
    Inventors: David W. Speicher, Kurt T. Barnhart, Lynn A. Beer